SALT LAKE CITY – October 1, 2007 – Coherex Medical™, Inc., a privately held medical device company, today announced it has been invited to deliver a presentation at In3 East, Boston, one of the leading venture capital and strategic partnership conferences in the United States.

Coherex executives will present information about the company and its Coherex FlatStent™ PFO Closure System, a new medical technology designed to help close a heart defect – a Patent Foramen Ovale – that occurs in approximately 25 percent of the population.

The Coherex presentation will be delivered on Thursday, October 4, 2007 at 5:40 p.m. (EDT) during the In3 East conference which will be held at the Westin Hotel – Copley Place in Boston. Conference attendees will also be able to meet one-on-one with Coherex executives at the company’s product exhibit during the networking reception following the Coherex presentation.

Although this will be Coherex’ first presentation at a VC conference, the company has previously raised more than $11.5 million in private funding, including $8.525 million in an A Round of venture capital funding that was announced in April 2007 and led by Oxford Biosciences and vSpring Capital.

About Patent Foramen Ovale (PFO) Heart Defects
A foramen ovale is a tunnel-like opening between the upper chambers of the heart that is present in all fetuses. This opening allows blood to bypass the lungs until a baby is born and draws its first breath.  Normally, the foramen ovale closes soon after an infant is born. However, should this opening fail to close naturally within a year after birth, the opening is said to remain patent and the condition is called a patent foramen ovale (PFO).

A common heart defect that occurs in roughly 25 percent of the population, PFOs can allow blood to bypass the lungs by shunting directly from the right side of the heart to the left, thus
•    increasing the likelihood of blood clots in the heart flowing directly to the brain; and
•    preventing the filtration of chemicals out of the blood that occurs in the lungs.

While the presence of a PFO does not present risks to all people who have this heart defect, the condition has been linked to at least two medical conditions that may benefit greatly from PFO closure: cryptogenic stroke and migraine.

According to the Stroke Council of the American Heart Association, approximately 500,000 strokes each year worldwide may be attributable to the presence of a PFO, which represents a potential annual market size of close to $2 billion.

On the other hand, migraine is a common disorder, affecting approximately 12 percent of adult populations in Western countries. While a connection between PFOs and migraines has not yet been proven scientifically, significant anecdotal evidence exists to suggest a possible relationship. As such, the worldwide market potential for PFO closure to treat migraine patients has been estimated to be more than $15 billion per year.

About the Coherex FlatStent PFO Closure System
The Coherex FlatStent PFO Closure System is similar in use and function to self-expanding vascular stents which are widely used by Interventional Cardiologists during heart surgery. However, Coherex’ patent-pending FlatStent Closure System incorporates a unique fusion of PFO closure mechanisms and accepted medical practices in a design expected to utilize a body’s defense systems  to help naturally seal a PFO tunnel (after the Coherex FlatStent is implanted in a heart).

About Coherex Medical
Formed in 2003 by Brian Whisenant, M.D., Coherex Medical is focused on addressing structural heart disease and conditions through medical devices. For more information, please visit www.coherex.com or call 801-433-9900.

Coherex, Coherex Medical and FlatStent are each trademarks of Coherex Medical, Inc. All other trademarks are the properties of their respective owners.

CONTACTS:
Trent Loveless, Coherex Medical, 801-433-9900, tloveless@coherex.com or
David Politis, Politis Communications, 801-523-3730(w)/801-556-8184(c), dpolitis@politis.com

09/22/09
Coherex Medical Signs Exclusive Distribution Agreement with Abbott

09/22/09
Coherex Medical Announces Lunch Symposium during TCT 2009
(the Transcatheter Cardiovascular Therapeutics Conference) on Tues., Sept. 22, 2009

08/20/09
Coherex Medical Closes $16.5 Million Series B Preferred Stock Financing

07/08/09
Coherex Medical’s Coherex FlatStent EF PFO Closure System Granted CE Mark Clearance for Closing PFOs – a Common Heart Defect; Company to Begin Sales/Marketing Efforts in Europe

07/08/09
CE Mark Clearance for Coherex Medical’s Coherex FlatStent EF PFO Closure System

10/13/08
Chronic Migraines Caused by a Hole in the Heart? “Highly Likely,” New Research Says

10/12/08
Coherex Medical Announces Breakfast Symposium and Executive Presentations During This Week’s TCT 2008 (the Transcatheter Cardiovascular Techniques Conference)

10/21/07
First “Live Case” Transmission of a PFO Closure Procedure Using the Coherex FlatStent PFO Closure System to be Presented at TCT 2007

10/03/07
Coherex Medical Successfully Completes First Human Cases with its Coherex FlatStent PFO Closure System as Company Begins COHEREX-EU Study to Seek CE Mark Clearance

10/03/07
Utah company's new stent may help repair heart defects

10/02/07
Coherex Medical to Begin its COHEREX-EU Study to Pursue CE Mark Clearance for its Coherex FlatStent PFO Closure System

10/01/07
Coherex Medical has been invited to deliver a presentation at In3 East, Boston, one of the leading venture capital and strategic partnership conferences in the United States

05/10/07
2007 Utah Innovation Awards Winners

04/17/07
2007 Utah Innovation Awards Finalists